This again supports the concept of combining targeted therapies in NETs, as previously shown to be effective: Combined inhibition of mTORC1/2, PI3K/mTORC1/2, PI3K/mTORC1/2/ERK or EGFR/PI3K/mTORC1 has shown promising anti-tumor potential in NETs in vitro [18, 28, 42, 45, 105]. This evidence concerns the gene PIK3CA and neoplasm.